No 1 (2021)

Cover Page

Full Issue

PDF(Russian)
Articles
Vaktsina KoviVak ot Tsentra im. Chumakova vykhodit v grazhdanskiy borot
Article E.
Abstract
Всего до конца года планируется выпустить не менее 10 млн доз, рассказал глава Минпромторга Денис Мантуров.
REMEDIUM. 2021;(1):2-3
views
CRA University - School of Clinical Trial Monitors: 10 years of success
Semenov-Tyan-Shanskiy V.L., Bal’Tserovich A.S., Sazonova A.N., Loginovskaya O.A., Verbitskaya E.V., Malikova E.A., Kolbin A.S., Zvartau E.E., Pavlovich D.M.
Abstract
This article presents the history and structure of the school of clinical trials monitors in Russia, the reasons for its opening in 2011, as well as the results of a survey of graduates. The authors discuss in detail what tasks they faced in creating a high-quality, modern, interactive educational program that is sustainable in the long term. Shows the important role of collaboration between academic institutions and business companies directly involved in clinical research on a daily basis. The structure of the course is presented, as well as teaching materials and electronic systems and technologies are used. Separately, the experience of operating a school during the COVID-19 pandemic is given, an analysis of the course functioning in fully online format, the positive and negative aspects of this approach. The second part of the article presents the results of a survey of graduates of the course for 9 years: from their satisfaction with training, to their further professional career (a total of 8 questions). In conclusion, the authors present their personal attitude to this educational project.
REMEDIUM. 2021;(1):4-8
views
Global Pharma Market 2021 Trends
Prozherina Y.
Abstract
The COVID-19 pandemic has had a transformative impact on all aspects of the pharmaceutical industry. In 2020, it forced all market players to take a new look at their usual activities, significantly improve the healthcare delivery methods and introduce innovations at an unprecedented pace [1]. This review presents the forecasts of analytical agencies regarding the development of the pharmaceutical market in 2021.
REMEDIUM. 2021;(1):9-11
views
Russian pharmaceutical market at the end of 2020
Kazova A., Kalinina N.
Abstract
Неблагоприятная эпидемическая обстановка и связанные с ней государственные расходы на медико-фармацев- тическую сферу придали дополнительный импульс росту российского фармрынка уже в первые месяцы 2020 г. Основными драйверами этого роста в средне- и долгосрочной перспективе по-прежнему останутся государственные инвестиции в закупки фармацевтической и медицинской продукции, а также реализация стратегии «Фарма-2030». Принятая еще в апреле 2019 г. данная стратегия предусматривает рост расходов на здравоохранение, дальнейшее импортозамещение, локализацию производства, а также развитие электронной коммерции в фармацевтическом ретейле.
REMEDIUM. 2021;(1):12-15
views
Reyting aptechnykh setey Rossii po itogam 2020 goda
Bespalov N., Rasshchupkin P.
Abstract
В январе текущего года произошло любопытное во всех отношениях событие: капитализация российского интернет-ретейлера «Озон» превысила биржевую оценку стоимости сети X5 Retail Group. Примечательно при этом, что выручка компаний за 2020 г. различается более чем в 10 раз, к тому же «Озон» не планировал в ближайшем будущем выплачивать дивиденды. По факту компании выдан поистине громадный кредит доверия, который в прошлом году, естественно, подогревался бумом развития дистанционных форматов торговли.
REMEDIUM. 2021;(1):16-16
views
Distributors-2020
Nechaeva Y.
Abstract
2020, with all its challenges, has been a test of strength for the distributor chains. After all, it was them on whom uninterrupted provision of population with medicines largely depended: timely supply of drugs to the pharmacies, dealing with manufacturers to bridge emerging deficiencies - these and other significant challenges have once again confirmed that distributors constitute an integral part of the product supply chain, and their significance is very high.
REMEDIUM. 2021;(1):17-19
views
Vladimir Parfenov: «Nesomnennyy potentsial neyroprotektivnykh sredstv zaklyuchaetsya v vozmozhnosti ikh ispol'zovaniya v samye rannie sroki razvitiya ishemicheskogo insul'ta»
Article E.
Abstract
Острые нарушения мозгового кровообращения - причины летальности и стойкой инвалидизации. Насколько часто россияне сталкиваются с этой патологией? Что приводит к развитию инсульта? Какова роль нейропротективной и нейротрофической терапии в остром и восстановительном периоде инсульта? На эти и другие вопросы мы просили ответить Владимира ПАРФЕНОВА, директора Клиники нервных болезней им. А.Я. Кожевникова Первого МГМУ им. И.М. Сеченова, д.м.н., профессора.
REMEDIUM. 2021;(1):20-22
views
Defeating stroke
Prozherina Y.P.
Abstract
Acute cerebrovascular accidents (ACVAs) rank among the leaders in the morbidity pattern of the adult population. The annual incidence of strokes per 1000 population in different countries around the world is 1.3 to 7.4 cases [1]. In addition, acute ischemic accidents (ischemic stroke, cerebral infarction) account for about 80% of all strokes in Russia [2]. The search for effective pharmacotherapy for such patients is one of the major challenges for modern medicine.
REMEDIUM. 2021;(1):23-26
views
Practice guidelines for the treatment of arterial hypertension in the era of COVID-19: 2020 ISH global hypertension practice review
Vodovozov A.
Abstract
Arterial hypertension (AH) remains one of the most urgent global health challenges. However, it added up to an equally dangerous challenge - COVID-19 in 2020. That is why the International Society of Hypertension (ISH) released the updated guidelines comprising the methods and drugs that had proven themselves to be the best in the recent randomized controlled trials. In some respects, they differ from the previously issued American and European guidelines, for example, in the very definition for hypertension, which blood pressure threshold should be considered high. However, all three documents are synchronous in terms of drug therapy: it is necessary to start administering antihypertensive drugs as early as possible and immediately use the most effective ones - inhibitors of the renin-angiotensin system (RAS) combined with other drugs that are chosen individually depending on the features of the course of hypertension in each individual patient. In addition, it has been found that RAS inhibitors have a positive effect on the course of COVID-19 in patients with hypertension, which only increased the relevance of the global consensus on hypertension therapy.
REMEDIUM. 2021;(1):27-32
views
Vera Prilepskaya: «Lechenie zhelezodefitsitnykh sostoyaniy u zhenshchin reproduktivnogo vozrasta pozvolyaet uluchshit' techenie beremennosti i perinatal'nye iskhody i zakonomerno snizit' materinskuyu smertnost'»
Article E.
Abstract
Железодефицитная анемия (ЖДА) - патологическое состояние, характеризующееся нарушением синтеза гемоглобина в результате дефицита железа. Наиболее часто ЖДА встречается у беременных женщин и кормящих матерей, негативно влияя как на их здоровье, так и на здоровье плода и новорожденного.О роли железа в организме, проблемах, связанных с его дефицитом, клинических проявлениях ЖДА и современных подходах к ее лечению мы решили поговорить с Верой Николаевной Прилепской, заместителем директора по научной работе, заведующей научно-поликлиническим отделением ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Министерства здравоохранения РФ, д.м.н., профессором.
REMEDIUM. 2021;(1):33-35
views
Life without iron deficiency
Prozherina Y., Shirokova I.
Abstract
Iron deficiency is the most common pathology worldwide. It can be fully compensated by using iron-containing supplements, which now achieve a strong position in Russia [1].
REMEDIUM. 2021;(1):36-40
views
Smart glucometers: revolution in diabetes management
Prozherina Y.
Abstract
The rapid spread of diabetes mellitus (DM) is one of the global health challenges around the world. In Russia, the number of registered patients reached 5.1 million in 2020 [1]. Today, it does not raise doubts that achieving good glycaemic control prevents or significantly reduces the risk of development and progression of chronic complications in patients with diabetes. With advances in technology, “smart” glucometers have been launched, significantly expanding options in diabetes management [2].
REMEDIUM. 2021;(1):43-45
views
In combat against viruses
Shirokova I., Prozherina Y.
Abstract
The late 20th century and the early 21st century have been marked by the explosive development of virology due to activation of viral infections. New mutations of the influenza virus, high incidence of persistent virus infections in humans, as well as respiratory viral diseases that have not yet been eradicated has boosted further development of this direction [1].
REMEDIUM. 2021;(1):43-49
views
Surfactant therapy in combination treatment of COVID-19 related acute respiratory distress syndrome
Gubaidullin R.R., Kuzin A.P., Kulakov V.V.
Abstract
Introduction. The COVID-19 pandemic caused an outbreak of viral lung infections with severe acute respiratory syndrome complicated with acute respiratory failure. Despite the fact that the pandemic has a lengthened run, none of the therapeutic approaches have proved to be sufficiently effective according to the evidence-based criteria. We consider the use of surfactant therapy in patients with severe viral pneumonia and acute respiratory distress syndrome (ARDS) as one of the possible methods for treating COVID-19 related pneumonia. Objective. To prove the clinical efficacy and safety of orally inhaled Surfactant-BL, an authorized drug, in the combination therapy of COVID-19 related ARDS.Materials and methods. A total of 38 patients with COVID-19 related severe pneumonia and ARDS were enrolled in the study. Of these, 20 patients received the standard therapy in accordance with the temporary guidelines for the prevention, diagnosis and treatment of the novel coronavirus infection (COVID-19) of the Ministry of Health of the Russian Federation, version 9. And 18 patients received the surfactant therapy in addition to the standard therapy. Surfactant-BL was used in accordance with the instructions on how to administer the drug for the indication - prevention of the development of acute respiratory distress syndrome. A step-by-step approach to the build-up of the respiratory therapy aggressiveness was used to manage hypoxia. We used oxygen inhalation via a face mask with an oxygen inflow of 5-15 l/min, high- flow oxygen therapy via nasal cannulas using Airvo 2 devices, non-invasive lung ventilation, invasive lung ventilation in accordance with the principles of protective mechanical ventilation.
REMEDIUM. 2021;(1):50-56
views
Implementation of the quality management system in the medical industry and assessment of its compliance with the requirements of the EAEU
Gertsik Y.G., Plutnitskiy A.N., Nizamova E.R.
Abstract
The paper considers the main aspects and mechanisms of the quality management system implementation at the enterprises of the medical industry, their impact on the safety of circulation of medical devices in the territories of the Eurasian Economic Union member states. Based on the results of the analysis, conclusions are drawn about the applicability and significance of the considered provisions of the quality management system. The aim of the work is to analyze the main provisions of the Federal Law “On Amendments to certain Legislative Acts of the Russian Federation on the circulation of medical devices” draft and the possibilities of their practical application. The draft of the law establishes that the production of medical devices, which are subject to state registration, must meet the requirements for the implementation, maintenance and evaluation of the quality management system of medical devices, depending on the potential risk of their usage, approved by the Government of the Russian Federation. The following general scientific methods are used in the work: analysis and synthesis, system methods, as well as profile-economic, including controlling methods. The scientific novelty of the work lies in the generalization, analysis of the materials considered and in the formation of proposals for certain areas of implementation of the quality management system and conclusions on the development of integration in the medical industry of the member countries of the Eurasian Economic Union as a result of the analysis.
REMEDIUM. 2021;(1):57-62
views
Technology and innovation in the pharmaceutical industry
Prozherina Y.
Abstract
In recent years, technology and innovation have moved in leaps and bounds, changing all sectors including healthcare and pharmaceutics. The use of Big Data and process automation are driving rapid progress. The most modern approaches are being introduced into pharmacies and pharmaceutical enterprises even today.
REMEDIUM. 2021;(1):63-64
views
Management by objectives method in the government support arrangements for the public pharmacare system
Tarabukina S.M., Dremova N.B.
Abstract
The article proposes an algorithm for developing an object-oriented government program to build up the public pharmacare system in the Arctic areas of the Republic of Sakha (Yakutia). The need for combined efforts and competences of professional public organizations, business entities, executive and municipal authorities to ensure the efficiency and effectiveness of this support is substantiated.
REMEDIUM. 2021;(1):65-67
views
New old trends. Advertising practice
Borzova M.
Abstract
Law enforcement practice in the sphere of drug advertising continues to be one of the most challenging and controversial regulatory areas. Market players develop industry guidelines, companies enact by-laws to deal with advertising materials and risk mitigation strategies. However, life always makes adjustments even to the application of well-established algorithms. Some approaches of the law enforcers get deeper roots, while others grow more and more detailed, which often needs to be reflected in the internal policies of advertisers and advertising distributors. The antimonopoly authority practice was no exception in 2020. In this regard, the article will provide a brief review of the key, in our opinion, decisions of law enforcement authorities and summarize the old and new interpretations.
REMEDIUM. 2021;(1):68-71
views
Investment activity of pharmaceutical enterprises:intermediate results for 2020
Romanova S.
Abstract
The investment activities of pharmaceutical enterprises were analysed using the data from the state statistical reporting form No. P-2 “Information on investments to non-financial assets” (quarterly).
REMEDIUM. 2021;(1):72-76
views
Dvizhenie - tsel': kak izmenitsya lechenie SMA v etom godu v Rossii
Kuminova E.
Abstract
С 1 января 2021 г. вступил в силу новый перечень ЖНВЛП, который пополнился 25 наименованиями, среди них - один из немногих препаратов для патогенетического лечения спинальной мышечной атрофии (СМА) нусинерсен. Это означает, что теперь он будет закупаться государством по фиксированной предельной отпускной цене, равной5 138 690 78 руб. за упаковку. Такую сумму производитель препарата компания Янссен заявила к регистрации на основании минимальной референтной цены, что на четверть ниже средней цены государственных закупок в 2020 г. О значимости этого события мы поговорили с экспертами.
REMEDIUM. 2021;(1):77-81
views
Glavnaya zadacha - ukreplenie immuniteta
Shirokova I.
Abstract
В последнее время в мире отмечается повышенный спрос на витамины, минералы и БАД, что привело к значительному росту данного сегмента рынка. Согласно прогнозам, к 2024 г. он достигнет 278,02 млрд долл., причем значительную часть этого дохода будут составлять добавки на основе витаминов1.
REMEDIUM. 2021;(1):82-82
views
TOP-pozitsii. Pokazateli vedushchikh mirovykh i otechestvennykh proizvoditeley i distrib'yuterov
Article E.
Abstract
Производство медицинской продукции за 2020 год Фармацевтическая реклама ЛП и БАД в российских СМИ в январе 2021 года ТОП-20 крупнейших рекламодателей и рекламируемых марок ЛП и БАД в Российских СМИ* в январе 2021 года
REMEDIUM. 2021;(1):83-84
views

Mailing Address

Address: 105064, Moscow, st. Vorontsovo Pole, 12, building 1

Email: redactor@remedium-journal.ru

Phone: +7(495) 917-48-86



Principal Contact

Sherstneva Elena Vladimirovna
EXECUTIVE SECRETARY
National research Institute of public health named after N. A. Semashko

105064, Vorontsovo Pole st., 12, Moscow


Email: redactor@remedium-journal.ru

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies